INTRODUCTION: E4599 compared carboplatin and paclitaxel with (PCB) or without (PC) bevacizumab in patients with advanced-stage non-small cell lung cancer. Bevacizumab improved overall survival. However, an unplanned subset analysis did not show a survival benefit for females treated with bevacizumab. METHODS: Known prognostic factors and toxicities were compared by sex. Proportional hazards models of survival with multiple factor combinations were used to adjust for treatment effect. RESULTS: The analysis includes 850 patients. The median survival was 8.7 months (PC) versus 11.7 months (PCB) for males (p = 0.001) and 13.1 months (PC) versus 13.3 months (PCB) for females (p = 0.87). Progression-free survival and response rate on the PCB arm were 6.3 months and 29% for males and 6.2 months and 41% for females (p > 0.05). Progression-free survival and response rate on the PC arm were 4.3 months and 16% for males and 5.3 months and 14% for females (p > 0.05). No significant demographic differences were seen between the two arms for males, whereas fewer females on the PCB arm had liver metastasis (PCB 11.7% versus PC 23.2%, p = 0.003). Adverse events with a sex difference on the PCB arm included severe hypertension (males: 4.2%, females: 9.9%, p = 0.02), constipation (males: 1.4%, females: 4.7%, p = 0.05), and abdominal pain (males: 0.9%, females: 5.2%, p = 0.01). In the proportional hazards model adjusting for the other factors, the test for a sex by treatment interaction was not significant (p = 0.09). CONCLUSIONS: Multiple factors may contribute to the apparent sex-specific differences in efficacy of bevacizumab noted in this study.
RCT Entities:
INTRODUCTION: E4599 compared carboplatin and paclitaxel with (PCB) or without (PC) bevacizumab in patients with advanced-stage non-small cell lung cancer. Bevacizumab improved overall survival. However, an unplanned subset analysis did not show a survival benefit for females treated with bevacizumab. METHODS: Known prognostic factors and toxicities were compared by sex. Proportional hazards models of survival with multiple factor combinations were used to adjust for treatment effect. RESULTS: The analysis includes 850 patients. The median survival was 8.7 months (PC) versus 11.7 months (PCB) for males (p = 0.001) and 13.1 months (PC) versus 13.3 months (PCB) for females (p = 0.87). Progression-free survival and response rate on the PCB arm were 6.3 months and 29% for males and 6.2 months and 41% for females (p > 0.05). Progression-free survival and response rate on the PC arm were 4.3 months and 16% for males and 5.3 months and 14% for females (p > 0.05). No significant demographic differences were seen between the two arms for males, whereas fewer females on the PCB arm had liver metastasis (PCB 11.7% versus PC 23.2%, p = 0.003). Adverse events with a sex difference on the PCB arm included severe hypertension (males: 4.2%, females: 9.9%, p = 0.02), constipation (males: 1.4%, females: 4.7%, p = 0.05), and abdominal pain (males: 0.9%, females: 5.2%, p = 0.01). In the proportional hazards model adjusting for the other factors, the test for a sex by treatment interaction was not significant (p = 0.09). CONCLUSIONS: Multiple factors may contribute to the apparent sex-specific differences in efficacy of bevacizumab noted in this study.
Authors: David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: J P O'Connell; M G Kris; R J Gralla; S Groshen; A Trust; J J Fiore; D P Kelsen; R T Heelan; R B Golbey Journal: J Clin Oncol Date: 1986-11 Impact factor: 44.544
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Antonio L Visbal; Brent A Williams; Francis C Nichols; Randolph S Marks; James R Jett; Marie-Christine Aubry; Eric S Edell; Jason A Wampfler; Julian R Molina; Ping Yang Journal: Ann Thorac Surg Date: 2004-07 Impact factor: 4.330
Authors: M Paesmans; J P Sculier; P Libert; G Bureau; G Dabouis; J Thiriaux; J Michel; O Van Cutsem; R Sergysels; P Mommen Journal: J Clin Oncol Date: 1995-05 Impact factor: 44.544
Authors: Nikki M Carroll; Thomas Delate; Alex Menter; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Elizabeth T Loggers; Debra P Ritzwoller Journal: J Oncol Pract Date: 2015-06-09 Impact factor: 3.840
Authors: Debra P Ritzwoller; Nikki M Carroll; Thomas Delate; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Elizabeth T Loggers; Alex Menter Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: Julia C F Quintanilha; Jin Wang; Alexander B Sibley; Chen Jiang; Amy S Etheridge; Fei Shen; Guanglong Jiang; Flora Mulkey; Jai N Patel; Daniel L Hertz; Elizabeth Claire Dees; Howard L McLeod; Monica Bertagnolli; Hope Rugo; Hedy L Kindler; William Kevin Kelly; Mark J Ratain; Deanna L Kroetz; Kouros Owzar; Bryan P Schneider; Danyu Lin; Federico Innocenti Journal: Br J Cancer Date: 2021-10-06 Impact factor: 9.075
Authors: Anne S Tsao; Jieling Miao; Ignacio I Wistuba; Nicholas J Vogelzang; John V Heymach; Frank V Fossella; Charles Lu; Mario R Velasco; Brandy Box-Noriega; James G Hueftle; Shirish Gadgeel; Mary W Redman; David R Gandara; Karen Kelly Journal: J Clin Oncol Date: 2019-08-06 Impact factor: 44.544
Authors: Suresh S Ramalingam; Mikhail Shtivelband; Ross A Soo; Carlos H Barrios; Anatoly Makhson; José G M Segalla; Kenneth B Pittman; Petr Kolman; Jose R Pereira; Gordan Srkalovic; Chandra P Belani; Rita Axelrod; Taofeek K Owonikoko; Qin Qin; Jiang Qian; Evelyn M McKeegan; Viswanath Devanarayan; Mark D McKee; Justin L Ricker; Dawn M Carlson; Vera A Gorbunova Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544